NCT00001486 is a clinical trial in Schizoaffective Disorder, sponsored by National Institute of Mental Health (NIMH).

Who is sponsoring NCT00001486?

NCT00001486 is sponsored by National Institute of Mental Health (NIMH).

What condition does NCT00001486 study?

NCT00001486 studies Schizoaffective Disorder, Schizophrenia.

Is NCT00001486 still recruiting?

NCT00001486 is currently completed. Last updated 1 April 2026.

Last reviewed 2026-04-01 · How we verify

NCT00001486

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genetic Study of Schizophrenia

Completed Last updated 1 April 2026

What this trial tests

trial in Schizoaffective Disorder in 4,914 participants. Completed.

Timeline

15 July 1995

Quick facts

Lead sponsor	National Institute of Mental Health (NIMH)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	4,914
Start date	15 July 1995
Sites	1 location across United States

Conditions studied

Schizoaffective Disorder — all drugs for Schizoaffective Disorder →
Schizophrenia — all drugs for Schizophrenia →

Sponsor

National Institute of Mental Health (NIMH)

Who can join

Adults 18 to 55, any sex, with Schizoaffective Disorder or Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Is gray matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometry study of patients with schizophrenia and their healthy siblings.
Honea RA, Meyer-Lindenberg A, Hobbs KB, Pezawas L, et al · · 2008 · cited 157× · PMID 17689500 · DOI 10.1016/j.biopsych.2007.05.027
Investigation of anatomical thalamo-cortical connectivity and FMRI activation in schizophrenia.
Marenco S, Stein JL, Savostyanova AA, Sambataro F, et al · · 2012 · cited 130× · PMID 21956440 · DOI 10.1038/npp.2011.215
Dissecting transcriptomic signatures of neuronal differentiation and maturation using iPSCs.
Burke EE, Chenoweth JG, Shin JH, Collado-Torres L, et al · · 2020 · cited 126× · PMID 31974374 · DOI 10.1038/s41467-019-14266-z
Magnetoencephalographic gamma power reduction in patients with schizophrenia during resting condition.
Rutter L, Carver FW, Holroyd T, Nadar SR, et al · · 2009 · cited 81× · PMID 19288463 · DOI 10.1002/hbm.20746
Genetic modulation of GABA levels in the anterior cingulate cortex by GAD1 and COMT.
Marenco S, Savostyanova AA, van der Veen JW, Geramita M, et al · · 2010 · cited 57× · PMID 20357758 · DOI 10.1038/npp.2010.35
Electrophysiological measures from human iPSC-derived neurons are associated with schizophrenia clinical status and predict individual cognitive performance.
Page SC, Sripathy SR, Farinelli F, Ye Z, et al · · 2022 · cited 56× · PMID 35017298 · DOI 10.1073/pnas.2109395119
Epistatic interaction between COMT and DTNBP1 modulates prefrontal function in mice and in humans.
Papaleo F, Burdick MC, Callicott JH, Weinberger DR. · · 2014 · cited 54× · PMID 24145376 · DOI 10.1038/mp.2013.133
Polygenic risk score increases schizophrenia liability through cognition-relevant pathways.
Toulopoulou T, Zhang X, Cherny S, Dickinson D, et al · · 2019 · cited 52× · PMID 30535067 · DOI 10.1093/brain/awy279

Verify or expand the search:

Other recruiting trials for Schizoaffective Disorder

Currently open trials in the same condition.

NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
NCT07098169 — Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy · NA · recruiting
NCT06865937 — Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33) · NA · recruiting
NCT06586164 — Enhancing Rehabilitation for Veterans With Serious Mental Illness · NA · recruiting
NCT06562608 — Anticholinergic Deprescription in Schizophrenia · Phase 4 · recruiting

Other National Institute of Mental Health (NIMH) trials

Trials by the same sponsor.

NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT05652465 — Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder · Phase 2 · suspended
NCT07027839 — Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B) · Phase 1 · recruiting
NCT06920628 — PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 In · Phase 1 · recruiting
NCT06874205 — Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00001486 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Mental Health (NIMH)
Last refreshed: 1 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00001486.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing